Chemical inhibitors of ZUFSP can interfere with its function through various mechanisms that impede cellular processes essential for the protein's activity. Oligomycin A, for instance, inhibits ATP synthase, leading to a depletion of cellular ATP levels, which are vital for energy-dependent enzymes like ZUFSP. Without sufficient ATP, ZUFSP's ability to engage in its enzymatic activities is compromised. Brefeldin A disrupts protein trafficking between the endoplasmic reticulum and Golgi apparatus, which is a crucial pathway for the proper localization and functionality of ZUFSP. Mislocalization caused by Brefeldin A can prevent ZUFSP from accessing its substrates, thereby inhibiting its function. MG132 acts as a proteasome inhibitor, leading to the accumulation of polyubiquitinated proteins, which may sequester ZUFSP away from its intended substrates. Similarly, Lactacystin and Epoxomicin are proteasome inhibitors that could reduce the functionality of ZUFSP by stabilizing proteins that may compete with or act as decoys for ZUFSP's enzymatic processes.
The second paragraph continues to outline the inhibition mechanisms of ZUFSP by selected chemicals. E-64 and Leupeptin inhibit cysteine and serine proteases, respectively. The inhibition of these proteases can result in an accumulation of proteins within the ubiquitin-proteasome pathway, where ZUFSP operates, potentially impeding ZUFSP's ability to interact with its substrates effectively. ALLN, additionally a proteasome inhibitor, could further inhibit the degradation of ubiquitin-protein conjugates, leading to a similar outcome of restricted ZUFSP activity. Chloroquine and 3-Methyladenine disrupt autophagic processes, with the former increasing lysosomal pH and the latter inhibiting autophagosome formation. These disruptions can alter the turnover of proteins that ZUFSP is involved with, leading to its inhibition. Concanamycin A and NH4Cl both act to raise the pH within lysosomes, a condition that can impact the degradation pathways crucial for ZUFSP's functionality. By impeding these degradation pathways, these chemicals can result in an indirect inhibition of ZUFSP. Each chemical, through its unique action on different cellular pathways and structures, can contribute to the inhibition of ZUFSP, thereby impeding its normal function within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Oligomycin A | 579-13-5 | sc-201551 sc-201551A sc-201551B sc-201551C sc-201551D | 5 mg 25 mg 100 mg 500 mg 1 g | $179.00 $612.00 $1203.00 $5202.00 $9364.00 | 26 | |
Inhibits ATP synthase which leads to a decrease in cellular ATP levels, indirectly inhibiting energy-dependent processes including those required for ZUFSP function. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Disrupts protein trafficking between the endoplasmic reticulum and Golgi apparatus, which can result in the mislocalization and subsequent functional inhibition of ZUFSP, as proper localization is critical for its activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Proteasome inhibitor that can lead to the accumulation of polyubiquitinated proteins, potentially sequestering ZUFSP and preventing it from accessing its substrates. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
Irreversibly inhibits cysteine proteases; while not a direct inhibitor of ZUFSP, it can limit the availability of ubiquitinated substrates for ZUFSP through inhibition of upstream proteolytic processes. | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | $73.00 $148.00 $316.00 $499.00 $1427.00 $101.00 | 19 | |
Inhibits serine and cysteine proteases which could lead to the accumulation of proteins that compete with or impede ZUFSP’s functional interactions in the ubiquitin-proteasome pathway. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Another proteasome inhibitor that, by preventing the degradation of ubiquitin-protein conjugates, could lead to reduced functionality of ZUFSP due to substrate unavailability. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Selective proteasome inhibitor that could indirectly inhibit ZUFSP by stabilizing proteins that may act as decoys or competitors for ZUFSP’s enzymatic activity. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Lysosomotropic agent that increases lysosomal pH and affects autophagy, potentially disrupting ubiquitin-dependent degradation pathways that ZUFSP is involved in. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $65.00 $261.00 | 113 | |
Inhibits autophagy by blocking autophagosome formation, potentially altering the turnover of proteins that ZUFSP might interact with or regulate. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
V-ATPase inhibitor that suppresses acidification of organelles like lysosomes, affecting the degradation pathways which ZUFSP may be involved with. | ||||||